Publications by authors named "N Karlı"
Migraine, a prevalent neurological disorder, affects approximately 14.1% of the global population and disproportionately impacts females. This debilitating condition significantly compromises quality of life, productivity, and incurs high healthcare costs, presenting a challenge not only to individuals but to societal structures as a whole.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates persistent pain symptoms in long COVID patients, specifically focusing on a cohort of 191 individuals who had mild-to-moderate COVID-19 and were analyzed 1.5 years later.
- About 31.9% of participants reported persistent pain, with headaches being the most common symptom (29.8%), followed by myalgia and neuropathic pain.
- The research highlights key predictors for these pain symptoms and suggests a connection between different types of pain, contributing to a better understanding of long COVID and potential intervention strategies.
Background: Migraine is a disease characterized by headache attacks. The disease is multifactorial in etiology and genetic and environmental factors play role in pathogenesis. Migraine can also be accompanied by psychiatric disorders like neurotism and obsessive compulsive disorder.
View Article and Find Full Text PDFBackground: The complexity of clinical practice extends far beyond the controlled settings of trials, and there is a need for real-world studies aimed at identifying which patients will respond to anti-CGRP monoclonal antibodies in different countries. This study aimed to investigate the efficacy and safety of galcanezumab in treating migraine in a real-life setting in Turkey, as well as identify predictors of treatment response.
Methods: A total of 476 patients who diagnosed with migraine according to ICHD-3 criteria and treated with galcanezumab by headache specialists were voluntarily participated in this cross-sectional study.
Background: Intravenous immune globulin (IVIg) is frequently used in some neurological diseases and is also the first-line therapy in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. We aimed to evaluate the frequency and characteristics of headaches, which is one of the most common side effects of IVIg treatment.
Methods: Patients who received IVIg treatment for neurological diseases were prospectively enrolled in 23 centers.